What Is the Melanocortin Receptor System?
The melanocortin receptor family consists of five G-protein-coupled receptor subtypes, designated MC1R through MC5R. These receptors are activated by endogenous melanocortin peptides derived from pro-opiomelanocortin (POMC), including α-MSH, β-MSH, γ-MSH and adrenocorticotropic hormone (ACTH). Each receptor subtype has a distinct tissue distribution and a different set of documented physiological associations:
MC1R - primarily studied in melanocytes and skin pigmentation; also investigated in inflammatory and immunological contexts.
MC2R - the ACTH receptor, primarily associated with adrenal steroidogenesis.
MC3R - studied in the central nervous system, energy homeostasis and metabolism.
MC4R - widely studied in the central nervous system, with documented roles in energy balance, appetite and sexual function research.
MC5R - investigated in exocrine gland function and various peripheral tissues.
The melanocortin system is also regulated by endogenous antagonists, including agouti and agouti-related protein (AgRP), which adds complexity to any interpretation of receptor-agonist activity in vivo.
Which Receptors Does Bremelanotide Activate?
The prescribing information for Vyleesi (bremelanotide injection) describes bremelanotide as a melanocortin receptor agonist with agonist activity at multiple receptor subtypes. FDA labeling reports the following order of receptor potency: MC1R > MC4R > MC3R > MC5R > MC2R. At therapeutically relevant concentrations, MC1R and MC4R are considered the more relevant receptor interactions. The labeling also notes that the precise mechanism underlying the clinical improvement in HSDD is not fully characterized.
This means that bremelanotide should not be described as a "selective MC4R agonist" or as acting through a single confirmed pathway. Its receptor profile is broader, and the relationship between specific receptor activation and the observed clinical effect remains an area of ongoing research interpretation. For the current FDA labeling, see the Vyleesi prescribing information.
For research buyers, the practical implication is that receptor-study data should be reported with the specific assay conditions, receptor subtype and reference compound clearly stated. A generic claim that a material "activates MC4R" without specifying the assay format, concentration range and positive control is not sufficient to support a receptor-activity claim.
Why Does the Cyclic Structure Matter?
Bremelanotide is a synthetic cyclic heptapeptide with the condensed sequence Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH, where the side chains of aspartic acid (Asp) and lysine (Lys) form an internal lactam bridge. This cyclic structure is not a cosmetic detail; it has several implications for receptor interaction and material characterization:
Conformational restriction: The lactam bridge constrains the peptide backbone, favoring a specific three-dimensional conformation that is studied for receptor binding. Linear analogs may adopt a wider range of conformations and may show different receptor-binding profiles.
Receptor interaction studies: The cyclic design is intended to present the conserved His-Phe-Arg-Trp pharmacophore in a conformation that favors melanocortin receptor interaction. This is a design rationale supported by structure-activity research, not a guarantee of a specific clinical effect.
Analytical identity: Because cyclization is a defining structural attribute, analytical characterization should provide evidence consistent with the intended cyclic structure. Intact-mass LC-MS supports molecular identity but does not by itself establish the exact lactam-bridge connectivity or D-Phe stereochemistry; appropriate orthogonal methods may therefore be required depending on the analytical objective.
Stability considerations: Bremelanotide can undergo multiple degradation pathways under stress conditions. Recent stability research has reported deacetylation, peptide-bond hydrolysis, oxidation and epimerization-related degradation products. The specific degradation profile depends on conditions such as pH, temperature, oxidation and light exposure, so stability claims should be supported by product-specific data.
The presence of D-phenylalanine (D-Phe) in the sequence is also an identity attribute. D-Phe and L-Phe have the same nominal molecular mass, so intact-mass LC-MS cannot distinguish them by mass alone. Stereochemical confirmation requires appropriate orthogonal methods when the configuration is critical to the material's identity.
Receptor Agonism Is Not the Same as a Guaranteed Clinical Outcome
A common error in peptide marketing is to equate in vitro receptor agonism with a guaranteed clinical effect. These are different levels of evidence, and they should not be conflated:
In vitro receptor studies - measure binding affinity, functional potency or signaling pathway activation in cell-based assays. These results are assay-dependent and do not predict clinical efficacy.
Animal studies - may show physiological or behavioral effects in specific animal models, but species differences in receptor distribution, pharmacokinetics and metabolism limit direct extrapolation to humans.
Clinical studies - evaluate safety and efficacy in human subjects under defined protocols, with specific formulations, doses and patient populations.
Approved finished product labeling - reflects the regulatory evaluation of a specific drug product, including its formulation, delivery device, indication and contraindications.
Supplier bulk research material - is a raw chemical or peptide intended for laboratory use. Its quality must be verified independently; it does not inherit the clinical data or regulatory status of an approved product.
A material that shows receptor agonism in an in vitro assay is not automatically equivalent to an approved drug product, even if both contain the same peptide molecule. The formulation, purity, impurity profile, sterility, delivery route and dose all differ between a bulk research powder and a finished prescription product.
Why Approved-Product Safety Data Should Be Kept Separate
FDA labeling for Vyleesi reports product-specific safety findings including transient blood-pressure increases, nausea and focal hyperpigmentation. These findings belong to the approved finished product, its studied dose and patient population. They should not be used to establish the safety profile of an unrelated bulk bremelanotide acetate research-powder batch or to provide consumer-use guidance.
Why Clinical Findings Cannot Validate an Unrelated Research-Powder Batch
Clinical evidence for an approved finished product does not validate the identity, purity or performance of an unrelated research-powder batch. Bulk material must be evaluated independently using its own batch-specific analytical documentation, including identity, purity, assay and other applicable quality attributes.
Research Questions Supported by Well-Characterized PT-141 Material
Well-characterized bremelanotide acetate powder, with verified identity and batch-specific analytical documentation, can support a range of laboratory research questions:
Receptor binding studies: Evaluating binding affinity and selectivity across melanocortin receptor subtypes under defined assay conditions.
Functional signaling assays: Measuring functional signaling endpoints appropriate to the selected receptor assay in receptor-expressing cell lines.
Analytical method development: Developing and validating HPLC, LC-MS, ion chromatography and other methods for bremelanotide identification and quantification.
Cyclic peptide structure research: Studying the relationship between the lactam bridge, conformational restriction and receptor interaction.
Impurity characterization: Identifying and quantifying related substances, degradation products and residual solvents.
Stability and degradation pathway studies: Evaluating the effects of temperature, pH, light and storage conditions on peptide integrity over time.
These are legitimate research applications for well-characterized material. They do not constitute clinical use, and they should be conducted under appropriate laboratory safety and regulatory frameworks.
FAQ
Is bremelanotide a selective MC4R agonist?
No. Bremelanotide is described in the approved product labeling as a melanocortin receptor agonist with activity at multiple receptor subtypes. It is not a selective single-receptor agonist. MC1R and MC4R are considered more relevant at therapeutically relevant exposures, but the full receptor profile is broader.
Which melanocortin receptors interact with PT-141?
PT-141 (bremelanotide) has been reported to interact with several melanocortin receptor subtypes in receptor-binding and functional studies. The approved product labeling identifies MC1R and MC4R as more relevant at therapeutic exposures, but the specific assay conditions and concentration range should be stated when reporting receptor-activity data.
Is the clinical mechanism completely understood?
No. The prescribing information for Vyleesi explicitly states that the mechanism by which bremelanotide improves HSDD is not fully understood. Receptor agonism is a laboratory-level observation, but the relationship between specific receptor activation and the clinical effect remains an area of ongoing research interpretation.
Why is PT-141 cyclized?
PT-141 contains an internal lactam bridge between the side chains of aspartic acid and lysine, which constrains the peptide conformation. This cyclic structure is studied for its effect on receptor binding and stability relative to linear analogs. The cyclic identity must be confirmed analytically; HPLC retention time alone does not prove correct lactam-bridge formation.
Can research-powder results be compared directly with a finished prescription drug?
No. Bulk research powder and an approved finished drug product differ in formulation, purity, impurity profile, sterility, delivery route and dose. Clinical data for the approved product cannot be used to validate the quality or efficacy of an unrelated research-powder batch. Each batch must be evaluated on its own analytical documentation.
References
1. U.S. Food and Drug Administration – Vyleesi (bremelanotide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf
2. PubChem – Bremelanotide. CID 9941379. CAS 189691-06-3. https://pubchem.ncbi.nlm.nih.gov/compound/Bremelanotide
3. DrugBank – Bremelanotide. DB11653. https://go.drugbank.com/drugs/DB11653
4. Forced degradation study of bremelanotide acetate: identification of degradation products using LC-MS/MS and in silico methods. 2026. PMID: 42485063. https://pubmed.ncbi.nlm.nih.gov/42485063/
Contact HDM Biotech
Looking for PT-141 acetate powder for laboratory research? HDM Biotech provides batch-specific COA, analytical documentation, sample support and bulk supply options according to the confirmed product specification.
Contact:
Whatsapp & Mobile: +86 19991242181
Email:sales@hdmbio.com